The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV...
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a...
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
NEW YORK , May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV ...
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying busines...
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV
NEW YORK , May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV ...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated...
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3...
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of...
Shareholders That Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV) Should Contact Levi & Korsinsky about Pending Class Action - ABBV
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the fe...
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report
Major U.S. equities indexes were mixed on the first day of a new trading week that will feature earnings reports from a slew of major corporations.
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc. (ABBV) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
3 Dividend Stocks to Buy and Hold for the Next Decade
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of AB...
Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease...
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its o...
Related Companies